Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to $110.4 million.

  • Immunocore Holdings' Operating Expenses rose 2497.0% to $110.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $422.0 million, marking a year-over-year increase of 1664.53%. This contributed to the annual value of $377.9 million for FY2024, which is 2268.93% up from last year.
  • Latest data reveals that Immunocore Holdings reported Operating Expenses of $110.4 million as of Q3 2025, which was up 2497.0% from $111.8 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year Operating Expenses high stood at $350.4 million for Q4 2022, and its period low was -$60.0 million during Q4 2021.
  • Over the past 5 years, Immunocore Holdings' median Operating Expenses value was $87.7 million (recorded in 2023), while the average stood at $71.4 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 68402.43% in 2022, then plummeted by 7516.45% in 2023.
  • Over the past 5 years, Immunocore Holdings' Operating Expenses (Quarter) stood at -$60.0 million in 2021, then soared by 684.02% to $350.4 million in 2022, then plummeted by 75.16% to $87.0 million in 2023, then grew by 18.57% to $103.2 million in 2024, then grew by 6.96% to $110.4 million in 2025.
  • Its Operating Expenses stands at $110.4 million for Q3 2025, versus $111.8 million for Q2 2025 and $96.7 million for Q1 2025.